Schizophrenia

Lancet

Volumn 363, Issue 9426, 2004, Pages 2063-2072

  Mueser, Kim T ^a,c   McGurk, Susan R ^b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c DARTMOUTH PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; RISPERIDONE; VALPROIC ACID;

AGRANULOCYTOSIS; AKATHISIA; APATHY; BEHAVIOR THERAPY; COGNITIVE DEFECT; COGNITIVE THERAPY; COMORBIDITY; CONFERENCE PAPER; DEVELOPING COUNTRY; DISABILITY; DISEASE COURSE; EMPLOYMENT; EXTRAPYRAMIDAL SYMPTOM; FAMILY THERAPY; HEREDITY; HUMAN; MENTAL DISEASE; MUSCLE STIFFNESS; NEGATIVE SYNDROME; PARKINSONISM; PATHOPHYSIOLOGY; POVERTY; PRIORITY JOURNAL; PSYCHOSIS; PSYCHOSOCIAL CARE; SCHIZOPHRENIA; SELF CARE; SOCIAL ADAPTATION; SOCIAL STATUS; SOCIAL SUPPORT; SUBSTANCE ABUSE; TARDIVE DYSKINESIA; TREMOR; WITHDRAWAL SYNDROME;

EID: 2942648152     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)16458-1     Document Type: Conference Paper

References (161)

1. Terkelsen KG, Menikoff A. Measuring costs of schizophrenia: implications for the post-institutional era in the US. Pharmacoeconomics. 8:1995;199-222
2. Geller JL. An historical perspective on the role of state hospitals viewed from the "revolving door" Am J Psychiatry. 149:1992;1526-1533
3. Rice DP. Economic burden of mental disorders in the United States. Economics Neuroscience. 1:1999;40-44
4. Knapp M. Costs of schizophrenia. Br J Psychiatry. 171:1997;509-518
5. Goeree R, O'Brien BJ, Goering P, et al. The economic burden of schizophrenia in Canada. Can J Psychiatry. 44:1999;464-472
6. Murray CJL, Lopez AD, eds. The global burden of disease and injury series, vol 1: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge, MA: Harvard University Press, 1996.
7. US Institute of Medicine. Neurological, psychiatric, and developmental disorders: meeting the challenges in the developing world. Washington, DC: National Academy of Sciences, 2001.
8. Jablensky A. The 100-year epidemiology of schizophrenia. Schizophr Res. 28:1997;111-125
9. Murray RM, Van Os J. Predictors of outcome in schizophrenia. J Clin Psychopharmacol. 18:(suppl 1):1998;2S-4
10. Angermeyer MC, Kuhn L, Goldstein JM. Gender and the course of schizophrenia: differences in treated outcome. Schizophr Bull. 16:1990;293-307
11. Häfner H. Onset and early course as determinants of the further course of schizophrenia. Acta Psychiatrica Scandinavica. 102:(suppl 407):2000;44-48
12. Häfner H, Löffler W, Maurer K, Hambrecht M, an der Heiden W. Depression, negative symptoms, social stagnation and social decline in the early course of schizophrenia. Acta Psychiatrica Scandinavica. 100:1999;105-118
13. Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE. Schizophrenia: manifestations, incidence, and course in different cultures - a World Health Organization ten-country study. Psychol Med Monograph Suppl. 20:1992;1-97
14. World Health Organization. Schizophrenia: an international follow-up study. Chichester: John Wiley & Sons, 1979.
15. Kraepelin E. Dementia praecox and paraphrenia. 1971;Krieger, New York
16. Bleuler E. Dementia praecox or the group of schizophrenias. 1950;International Universities Press, New York
17. World Health Organization. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: WHO, 1992.
18. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV), fourth edn. Washington, DC: American Psychiatric Association, 1994.
19. Peralta V, Cuesta MJ. The nosology of psychotic disorders: a comparison among competing classification systems. Schizophr Bull. 29:2003;413-425
20. Häfner H, an der Heiden W. Course and outcome of schizophrenia. Hirsch SR, Weinberger DR. Schizophrenia. second edn:2003;101-141 Blackwell Scientific, Oxford
21. Liddle PF. The symptoms of chronic schizophrenia: a re-examination of the positive-negative dichotomy. Br J Psychiatry. 151:1987;145-151
22. Fenton WS, McGlashan TH. Natural history of schizophrenia subtypes: II positive and negative symptoms and long term course. Arch Gen Psychiatry. 48:1991;978-986
23. Sayers SL, Curran PJ, Mueser KT. Factor structure and construct validity of the scale for the assessment of negative symptoms. Psychol Assess. 8:1996;269-280
24. Weisman AY, Nuechterlein KH, Goldstein MJ, Snyder KS. Expressed emotion, attitudes, and schizophrenic symptom dimensions. J Abnorm Psychol. 107:1998;355-359
25. Heaton R, Paulsen JS, McAdams LA, et al. Neuropsychological deficits in schizophrenics: relationship to age, chronicity, and dementia. Arch Gen Psychiatry. 51:1994;469-476
26. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull. 26:2000;119-136
27. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the epidemiologic catchment area (ECA) study. JAMA. 264:1990;2511-2518
28. Rosenberg SD, Goodman LA, Osher FC, et al. Prevalence of HIV, hepatitis B and hepatitis C in people with severe mental illness. Am J Public Health. 91:2001;31-37
29. Walsh E, Moran P, Scott C, et al. Prevalence of violent victimisation in severe mental illness. Br J Psychiatry. 183:2003;233-238
30. Mueser KT, Rosenberg SD, Goodman LA, Trumbetta SL. Trauma, PTSD, and the course of schizophrenia: an interactive model. Schizophr Res. 53:2002;123-143
31. Susser E, Struening EL, Conover S. Psychiatric problems in homeless men: lifetime psychosis, substance use, and current distress in new arrivals at New York City shelters. Arch Gen Psychiatry. 46:1989;845-850
32. de Leon J, Dadvand M, Canuso C, White AO, Stanilla JK, Simpson GM. Schizophrenia and smoking: an epidemiological survey at a state hospital. Am J Psychiatry. 152:1995;453-455
33. Huppert JD, Smith TE. Longitudinal analysis of subjective quality of life in schizophrenia: anxiety as the best symptom predictor. J Nerv Ment Dis. 189:2001;669-675
34. Addington D, Addington J, Patten S. Depression in people with first-episode schizophrenia. Br J Psychiatry. 172:(suppl 33):1998;90-92
35. Bartels SJ, Drake RE, Wallach MA, Freeman DH. Characteristic hostility in schizophrenic outpatients. Schizophr Bull. 17:1991;163-171
36. Inskip HM, Harris EC, Barraclough C. Lifetime risk of suicide for alcoholism, affective disorder and schizophrenia. Br J Psychiatry. 172:1998;35-37
37. Brown S. Excess mortality of schizophrenia: a meta-analysis. Br J Psychiatry. 171:1997;502-508
38. McGuffin P, Owen MJ, Farmer AE. Genetic basis of schizophrenia. Lancet. 346:1995;678-682
39. Cardno A, Marshall E, Coid B, et al. Heritability estimates for psychotic disorders: the Maudsley twin psychosis series. Arch Gen Psychiatry. 56:1999;162-168
40. Harrison PJ, Owen MJ. Genes for schizophrenia: recent findings and their pathophysiological implications. Lancet. 361:2003;417-419
41. Thaker GK, Carpenter WTJr. Advances in schizophrenia. Nat Med. 7:2001;667-671
42. Susser E, Lin S. Schizophrenia after prenatal exposure to the Dutch Hunger Winter of 1944-1945. Arch Gen Psychiatry. 49:1992;983-988
43. Takei N, Mortensen PB, Klaening U, et al. Relationship between in utero exposure to influenza epidemics and risk of schizophrenia in Denmark. Biol Psychiatry. 40:1996;817-824
44. Thomas HV, Dalman C, David AS, Gentz J, Lewis G, Allebeck P. Obstetric complications and risk of schizophrenia: effect of gender, age at diagnosis and maternal history of psychosis. Br J Psychiatry. 179:2001;409-414
45. Cannon TD, Jones PB, Murray RM. Obstetric complications and schizophrenia: historical and meta-analytic review. Am J Psychiatry. 159:2002;1080-1092
46. Cannon TD, Rosso IM, Hollister JM, et al. A prospective cohort study of genetic and perinatal influences in the etiology of schizophrenia. Schizophr Bull. 26:2000;351-366
47. van Os J, Marcelis M. The ecogenics of schizophrenia: a review. Schizophr Res. 32:1998;127-135
48. Bruce ML, Takeuchi DT, Leaf PJ. Poverty and psychiatric status: longitudinal evidence from the New Haven epidemiologic catchment area study. Arch GenPsychiatry. 48:1991;470-474
49. Dohrenwend BP, Levav I, Shrout PE, et al. Ethnicity, socioeconomic status, and psychiatric disorders: a test of the social causation-social selection issue. Dohrenwend BP. Adversity, stress, and psychopathology. 1998;285-318 Oxford University Press, New York
50. Fox JW. Social class, mental illness, and social mobility: the social selection-drift hypothesis for serious mental illness. J Health Soc Behav. 31:1990;344-353
51. Peen J, Dekker J. Admission rates for schizophrenia in the Netherlands: an urban/rural comparison. Acta Psychiatrica Scandinavica. 96:1997;301-305
52. Jablensky A. Schizophrenia: epidemiology. Curr Opin Psychiatry. 12:1999;9-28
53. Boydell J, van Os J, McKenzie K, et al. Incidence of schizophrenia in ethnic minorities in London: ecological study into interactions with environment. BMJ. 323:2001;1336-1338
54. Selten JP, Slaets J, Kahn RS. Schizophrenia in Surinamese and Dutch Antillean immigrants to the Netherlands: evidence of an increased incidence. Psychol Med. 27:1997;807-811
55. Rabkin J. Ethnic density and psychiatric hospitalization: hazards of minority status. Am J Psychiatry. 136:1979;1562-1566
56. Wright IC, Rabe-Hesketh S, Woodruff PWR, et al. Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry. 157:2000;16-25
57. Andreasen NC, Flashman L, Flaum M, et al. Regional brain abnormalities in schizophrenia measured with magnetic resonance imaging. JAMA. 272:1994;1763-1769
58. Byne W, Buchsbaum MS, Mattiace LA, et al. Postmortem assessment of thalamic nuclear volumes in subjects with schizophrenia. Am J Psychiatry. 159:2002;59-65
59. Lawrie SM, Abukmeil SS. Brain abnormality in schizophrenia: a systematic and quantitative review of volumetric magnetic resonance imaging studies. Br J Psychiatry. 172:1998;110-120
60. Narr KL, Thompson P, Sharma T, et al. 3D mapping of temporo-limbic regions and the lateral ventricles in schizophrenia: sex effects. Biol Psychiatry. 15:2000;84-97
61. Fannon D, Chitnis X, Doku V, et al. Features of structural brain abnormality detected in early first episode psychosis. Am J Psychiatry. 157:2000;1829-1834
62. McDonald C, Grech A, Toulopoulou T, et al. Brain volumes in familial and non-familial schizophrenic probands and their unaffected relatives. Am J Med Genet Neuropsych Genet. 114:2002;616-625
63. Andreasen NC. Linking mind and brain in the study of mental illnesses: a project for a scientific psychopathology. Science. 275:1996;1586-1593
64. Buchsbaum MS, Someya T, Teng CY, et al. PET and MRI of the thalamus in never-medicated patients with schizophrenia. Am J Psychiatry. 153:1996;191-199
65. Weinberger DR, Berman KF, Zec RF. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia: I - regional cerebral blood flow evidence. Arch Gen Psychiatry. 43:1986;114-124
66. Yurgelun-Todd DA, Waternaux CM, Cohen BM, et al. Functional magnetic resonance imaging of schizophrenic patients and comparison subjects during word production. Am J Psychiatry. 153:1996;200-205
67. Schultz SK, Andreasen NC. Schizophrenia. Lancet. 353:1999;1425-1430
68. Penn DL, Corrigan PW, Bentall RP, Racenstein JM, Newman L. Social cognition in schizophrenia. Psychol Bull. 121:1997;114-132
69. Pinkham AEBS, Penn DLPD, Perkins DOMD, Lieberman JMD. Implications for the neural basis of social cognition for the study of schizophrenia. Am J Psychiatry. 160:2003;815-824
70. Honey GD, Bullmore ET, Soni W, Varatheesan M, Williams SCR, Sharma T. Differences in frontal cortical activation by a working memory tasks after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. PNAS. 96:1999;13432-13437
71. Lim KO, Hedehus M, de Crespigny A, Menon V, Moseley M. Diffusion tensor imaging of white matter tracts in schizophrenia. Biol Psychiatry. 43:(suppl 8S):1998;11S
72. Burns H, Job M, Bastin H, et al. Structural disconnectivity in schizophrenia: a diffusion tensor magnetic resonance imaging study. Br J Psychiatry. 182:2003;439-443
73. Davis KL, Stewart DG, Friedman JI, et al. White matter changes in schizophrenia: evidence for mylen-related dysfunction. Arch Gen Psychiatry. 60:2003;815-824
74. Hyde TM, Ziegler JC, Weinberger DR. Psychiatric disturbances in metachromatic leukodystrophy: insights into the neurobiology of psychosis. Arch Neurol. 49:1992;401-406
75. Reischies FM, Baum K, Brau H, Hedde JP, Schwindt G. Cerebral magnetic resonance imaging findings in multiple sclerosis: relation to disturbance of affect, drive, and cognition. Arch Neurol. 45:1988;1114-1116
76. Allin M, Murray R. Schizophrenia: a neurodevelopmental or neurodegenerative disorder? Curr Opin Psychiatry. 15:2002;9-15
77. Sharma T, Lancaster E, Sigmundsson T, et al. Lack of normal pattern of cerebral asymmetry in familial schizophrenic patients and their relatives: the Maudsley family study. Schizophr Res. 40:1999;111-120
78. Weinberger DR, Marenco S. Schizophrenia as a neurodevelopmental disorder. Hirsch SR, Weinberger DR. Schizophrenia. second edn:2003;326-348 Blackwell Publishing, Oxford
79. Akbarian S, Vinuela A, Kim JJ, Potkin SG, Bunney WEJ, Jones EG. Distorted distribution of nicotinaminde-adenine dinucleotide phosphate-diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development. Arch Gen Psychiatry. 50:1993;178-187
80. Innocenti GM, Ansermet F, Parnas J. Schizophrenia, neurodevelopment and corpus callosum. Mol Psychiatry. 8:2003;261-274
81. Keshavan MS, Anderson S, Pettegrew JW. Is schizophrenia due to excessive synaptic pruning in the prefrontal cortex? The Feinberg hypothesis revisited. J Psychiatric Res. 28:1994;239-265
82. Feinberg I. Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence? J Psychiatric Res. 17:1982;319-334
83. Almeida OP, Howard RJ, Levy R, David AS. Psychotic states arising in late life (late paraphrenia): psychopathology and nosology. Br J Psychiatry. 166:1995;205-214
84. Häfner H, Maurer K, Löffler W, an der Heiden W, Hambrecht M, Schultze-Lutter F. Modeling the early course of schizophrenia. Schizophr Bull. 29:2003;325-340
85. Maurer K, Bentz C, Loffler W, Häfner H. Psychiatric handicap: precursor or social sequelae of schizophrenia? (Seeelische Behinderung: Vorlaufer oder soziale Folge der Schizophrenie?). Gesundheitswesen. 58:(suppl 1):1996;79-85
86. Thara R, Henrietta M, Joseph S, Rajkumar S, Eaton WW. Ten-year course of schizophrenia: the Madras longitudinal study. Acta Psychiatrica Scandinavica. 90:1994;329-336
87. Craig TJ, Siegel C, Hopper K, Lin S, Sartorius N. Outcome in schizophrenia and related disorders compared between developing and developed countries: a recursive partitioning re-analysis of the WHP SOSMD data. Br J Psychiatry. 170:1997;229-233
88. Kleinman A. Rethinking psychiatry: from cultural category to personal experience. 1988;Free Press, New York
89. Nuechterlein KH, Dawson ME. A heuristic vulnerability/stress model of schizophrenic episodes. Schizoph Bull. 10:1984;300-312
90. Kane JM, Marder SR. Psychopharmacologic treatment of schizophrenia. Schizophr Bull. 19:1993;287-302
91. Greden JF, Tandon R, eds. Negative schizophrenic symptoms: pathophysiology and clinical implications. Washington, DC: American Psychiatric Press, 1991.
92. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 60:2003;553-564
93. Lieberman JA, Tollefson G, Tohen M, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry. 160:2003;1396-1404
94. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: Internaltional Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 60:2003;82-91
95. Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry. 156:1999;990-999
96. Alvir JMJ, Lieberman JA, Safferman AZ. Do white-cell count spikes predict agranulocytosis in clozapine recipients? Psychopharmacol Bull. 31:1995;311-314
97. Harvey PD, Keefe R. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry. 158:2001;176-184
98. Herz MI, Marder SR. Schizophrenia: comprehensive treatment and management. 2002;Lippincott Williams & Wilkins, Philadelphia
99. Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia: a review of efficacy and risks of current combinations. Acta Psychiatrica Scandinavica. 106:2002;323-330
100. Covell NH, Jackson CT, Evans AC, Essock SM. Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophr Bull. 28:2002;17-29
101. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull. 23:1997;637-651
102. Azrin NH, Teichner G. Evaluation of an instructional program for improving medication compliance for chronically mentally ill outpatients. Behav Res Therapy. 36:1998;849-861
103. Fisher WH, Geller JL, Altaffer F, Bennett MB. The relationship between community resources and state hospital recidivism. Am J Psychiatry. 149:1992;385-390
104. Stein LI, Santos AB. Assertive community treatment of persons with severe mental illness. 1998;Norton, New York
105. Bond GR, Drake RE, Mueser KT, Latimer E. Assertive community treatment for people with severe mental illness: critical ingredients and impact on clients. Dis Manage Health Outcome. 9:2001;141-159
106. Burns T, Creed F, Fahy T, Thompson S, Tyrer P, White I. Intensive versus standard case management for severe psychotic illness: a randomised trial. Lancet. 353:1999;2185-2189
107. Muijen M, Cooney M, Strathdee G, Bell R, Hudson A. Community psychiatric nurse teams: intensive support versus generic care. Br J Psychiatry. 165:1994;211-217
108. Thornicroft G, Strathdee G, Phelan M, et al. Rationale and design: PRiSM psychosis study 1. Br J Psychiatry. 173:1998;363-370
109. Marshall M, Bond GR, Stein L, et al. The PRiSM Psychosis Study: design limitations, mistaken conclusions. Br J Psychiatry. 175:1999;501-503
110. Lefley HP. Family caregiving in mental illness. 1996;Sage, Thousand Oaks, CA
111. Butzlaff RL, Hooley JM. Expressed emotion and psychiatric relapse. Arch Gen Psychiatry. 55:1998;547-552
112. Pitschel-Walz G, Leucht S, Bäuml J, Kissling W, Engel RR. The effect of family interventions on relapse and rehospitalization in schizophrenia: a meta-analysis. Schizophr Bull. 27:2001;73-92
113. Mueser KT, Salyers MP, Mueser PR. A prospective analysis of work in schizophrenia. Schizophr Bull. 27:2001;281-296
114. Becker DR, Drake RE. A working life for people with severe mental illness. 2003;Oxford University Press, New York
115. Bond GR, Becker DR, Drake RE, et al. Implementing supported employment as an evidence-based practice. Psychiatric Services. 52:2001;313-322
116. Erickson DH, Beiser M, Iacono WG, Fleming JAE, Lin T. The role of social relationships in the course of first-episode schizophrenia and affective psychosis. Am J Psychiatry. 146:1989;1456-1461
117. Bellack AS, Mueser KT, Gingerich S, Agresta J. Social skills training for schizophrenia: a step-by-step guide, second edn. New York: Guilford Press, 2004.
118. Heinssen RK, Liberman RP, Kopelowicz A. Psychosocial skills training for schizophrenia: lessons from the laboratory. Schizophr Bull. 26:2000;21-46
119. Glynn SM, Marder SR, Liberman RP, et al. Supplementing clinic-based skills training with manual-based community support sessions: effects on social adjustment of patients with schizophrenia. Am J Psychiatry. 159:2002;829-837
120. Gingerich S, Mueser KT. Illness management and recovery. 2002;The West Institute, Concord, NH
121. Hogarty GE. Personal therapy for schizophrenia and related disorders: a guide to individualized treatment. 2002;Guilford Press, New York
122. Mueser KT, Corrigan PW, Hilton D, et al. Illness management and recovery for severe mental illness: a review of the research. Psychiatr Serv. 53:2002;1272-1284
123. Atkinson JM, Coia DA, Gilmour WH, Harper JP. The impact of education groups for people with schizophrenia on social functioning and quality of life. Br J Psychiatry. 168:1996;199-204
124. Birchwood M, Smith J, MacMillan F, et al. Predicting relapse in schizophrenia: the development and implementation of an early signs monitoring system using patients and families as observers, a preliminary investigation. Psychol Med. 19:1989;649-656
125. Tarrier N. Management and modification of residual positive psychotic symptoms. Birchwood M, Tarrier N. Innovations in the psychological management of schizophrenia. 1992;147-169 John Wiley & Sons, Chichester
126. Curson DA, Patel M, Liddle PF, Barnes TRE. Psychiatric morbidity of a long stay hospital population with chronic schizophrenia and implications for future community care. BMJ. 297:1988;819-822
127. Mueser KT, Douglas MS, Bellack AS, Morrison RL. Assessment of enduring deficit and negative symptom subtypes in schizophrenia. Schizophr Bull. 17:1991;565-582
128. Racenstein JM, Harrow M, Reed R, Martin E, Herbener E, Penn DL. The relationship between positive symptoms and instrumental work functioning in schizophrenia: a 10-year follow-up study. Schizophr Res. 56:2002;95-103
129. Fowler D, Garety P, Kuipers E. Cognitive behaviour therapy for psychosis: theory and practice. 1995;John Wiley & Sons, Chichester
130. Gould RA, Mueser KT, Bolton E, Mays V, Goff D. Cognitive therapy for psychosis in schizophrenia: an effect size analysis. Schizophr Res. 48:2001;335-342
131. Ridgely MS, Goldman HH, Willenbring M. Barriers to the care of persons with dual diagnoses: organizational and financing issues. Schizophr Bull. 16:1990;123-132
132. Mueser KT, Noordsy DL, Drake RE, Fox L. Integrated treatment for dual disorders: a guide to effective practice. 2003;Guilford Press, New York
133. Drake RE, Mueser KT, Brunette MF, McHugo GJ. A review of treatments for clients with severe mental illness and co-occurring substance use disorder. Psychiatric Rehab J (in press).
134. Lieberman JA, Perkins D, Belger A, et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry. 50:2001;884-897
135. McGlashan WH, Fenton WS. The positive-negative distinction in schizophrenia: review of natural history validators. Arch Gen Psychiatry. 49:1992;63-72
136. Birchwood M, Todd P, Jackson C. Early intervention in psychosis: the critical period hypothesis. Br J Psychiatry. 172:(suppl 33):1998;53-59
137. Cullberg J, Levander S, Holmqvist R, Mattsson M, Wieselgren IM. One-year outcome in first episode psychosis patients in the Swedish parachute project. Acta Psychiatrica Scandinavica. 106:2002;276-285
138. Malla AK, Norman RMG, Manchanda R, et al. Status of patients with first-episode psychosis after one year of phase-specific community-oriented treatment. Psychiatric Services. 53:2002;458-463
139. Lewis SW, Tarrier N, Haddock G, et al. Randomised controlled trial of cognitive-behavioural therapy in early schizophrenia: acute-phase outcomes. Br J Psychiatry. 181:2002;S91-97
140. Nordentoft M, Jeppesen P, Abel M, et al. OPUS study: suicidal behaviour, suicidal ideation and hopelessness among patients with first-episode psychosis: one-year follow-up of a randomised controlled trial. Br J Psychiatry. 181:(suppl 43):2002;S98-106
141. Yung AR, Phillips LJ, Yuen HP, et al. Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophr Res. 60:2003;21-32
142. Woods SW, Breier A, Zipursky RB, et al. Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol Psychiatry. 54:2003;453-464
143. McGorry PD, Yung AR, Phillips LJ, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry. 59:2002;921-928
144. Schulsinger F, Jablensky A. The national mental health programme in the United Republic of Tanzania: areport from WHO and DANIDA. Acta Psychiatrica Scandinavica. 83:(suppl 364):1991;1-132
145. Zhang M, He Y, Gittelman M, Wong Z, Yan H. Group psychoeducation of relatives of schizophrenic patients: two-year experiences. Psychiatry Clin Neurosci 1998; 52(suppl): S344-47.
146. Farina A. Stigma. In: Mueser KT, Tarrier N, eds. Handbook of social functioning in schizophrenia. Boston: Allyn and Bacon, 1998; 247-79.
147. Crisp AH, Gelder MG, Rix S, Meltzer HI, Rowlands OJ. Stigmatisation of people with mental illnesses. Br J Psychiatry. 177:2000;4-7
148. Corrigan PW, Penn DL. Lessons from social psychology on discrediting psychiatric stigma. Am Psychologist. 54:1999;765-776
149. Corrigan PW, Rowan D, Green A, et al. Challenging two mental illness stigmas: personal responsibility and dangerousness. Schizophr Bull. 28:2002;293-309
150. Weiner B. Judgments of responsibility: a foundation for a theory of social conduct. 1995;Guilford Press, New York
151. Link BG, Cullen FT, Frank J, Wozniak JF. The social rejection of former mental patients: understanding why labels matter. Am J Sociol. 92:1987;1461-1500
152. Page S. Effects of the mental illness label in: acceptance and rejection in the community. J Mental Health Soc Policy ; 7. 1995:1993;61-68
153. Mechanic D, McAlpine D, Rosenbield S, Davis D. Effects of illness attribution and depression on the quality of life among persons with serious mental illness. Social Sci Med. 39:1994;155-164
154. Haghighat R. A unitary theory of stigmatization: pursuit of self-interest and routes to destigmatization. Br J Psychiatry. 178:2001;207-215
155. Wahl OF. Depiction of mental illness in children's media. J Mental Health. 12:2003;249-258
156. Pinfold V, Toulmin H, Thornicroft G, Huxley P, Farmer P, Graham T. Reducing psychiatric stigma and discrimination: evaluation of educational interventions in UK secondary schools. Br J Psychiatry. 182:2003;342-346
157. Couture SM, Penn DL. Interpersonal contact and the stigma of mental illness: a review of the literature. J Mental Health. 12:2003;291-305
158. US Congress. Americans with disabilities act of 1990. Washington, DC: Senate and House of Representatives of United States, 1990.
159. Wahl OF. Media madness: public images of mental illness. 1995;Rutgers University Press, New Brunswick, NJ
160. Penn DL, Wykes T. Contacts for anti-stigma campaigns and organisations. J Mental Health. 12:2003;332-334
161. Sartorius N. Fighting schizophrenia and its stigma: a new world psychiatric association educational program. Br J Psychiatry. 170:1997;297